Gilead taps Nurix pro­tein de­grad­er op­tion for $20M

Four years af­ter first en­ter­ing a col­lab­o­ra­tion with Nurix, Gilead is pony­ing up an op­tion ex­er­cise pay­ment of $20 mil­lion to li­cense tar­get­ed pro­tein de­grad­er GS-6791.

It’s the first can­di­date to come from the agree­ment, with the po­ten­tial for $425 mil­lion in mile­stone pay­ments and low dou­ble-dig­it tiered roy­al­ties on prod­uct net sales.

GS-6791 is an oral IRAK4 de­grad­er that tar­gets in­flam­ma­to­ry re­spons­es. De­grad­ing IRAK4 could lead to po­ten­tial treat­ments in rheuma­toid arthri­tis and oth­er in­flam­ma­to­ry dis­eases, ac­cord­ing to a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER